Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage
biotech company, will highlight clinical data on LP-20, a novel MRI
contrast agent designed for diagnosing interstitial cystitis and
detecting bladder cancer at the 5th International Consultation on
Interstitial Cystitis Japan (ICICJ) in Kyoto, Japan, taking place
August 21-23, 2024.
LP-20, which has completed preclinical and proof-of-concept
human trials, is administered via catheter into the bladder. It
uses advanced MRI technology to identify bladder permeability
defects, aiding in the diagnosis of interstitial cystitis and
bladder pain syndrome (IC/BPS) and the detection of bladder cancer
progression to muscle invasive bladder cancer. Funded, in part by
the National Institute of Diabetes and Digestive and Kidney
Diseases (NIDDK), LP-20 shows promise as a rapid and cost-effective
diagnostic solution for these conditions.
Dr. Michael Chancellor, Chief Medical Officer at Lipella,
commented, “The use of MRI to measure bladder permeability defects
offers a potential breakthrough in diagnosing IC/BPS and bladder
cancer. This innovative imaging technique addresses significant
unmet needs in urology and could greatly enhance patient care. We
look forward to sharing our findings with the international
scientific community as we continue to develop needed therapeutics
for serious diseases.”
Professor Pradeep Tyagi from the University of Pittsburgh
Medical Center added, “LP-20 provides a valuable tool for
phenotyping IC/BPS, potentially streamlining patient identification
for clinical trials and improving timely access to effective
treatments.”
Convening international leaders in the field of interstitial
cystitis, the 5th International Consultation on Interstitial
Cystitis Japan will feature special lectures and workshops on
pelvic pathology, and the proceedings will be published in a
special issue of “The International Journal of Urology,” the
official English journal of the Japanese Urological
Association.
About LP-20
LP-20 is a dual-component MRI contrast agent designed to
identify bladder permeability defects. Administered via catheter,
it generates detailed MRI images to diagnose IC/BPS and monitor
bladder cancer progression. It represents a significant advancement
in bladder diagnostics, offering a non-invasive alternative to
traditional methods.
About Interstitial Cystitis/Bladder Pain Syndrome
(IC/BPS) and Bladder Cancer
IC/BPS is a challenging condition often diagnosed by exclusion.
Current diagnostic methods, including cystoscopy, are limited in
differentiating IC/BPS from pelvic floor dysfunction. A new
diagnostic tool for bladder permeability could expedite diagnosis
and reduce patient suffering. Bladder cancer diagnosis,
particularly for muscle invasive bladder cancer, traditionally
relies on invasive procedures like cystoscopy and biopsy. LP-20
aims to complement existing methods with a non-invasive,
early-detection imaging technique.
ABOUT LIPELLA PHARMACEUTICALS INC.
Lipella is a clinical-stage biotechnology company focused on
developing new drugs by reformulating the active agents in existing
generic drugs and optimizing these reformulations for new
applications. Additionally, Lipella maintains a therapeutic focus
on diseases with significant, unaddressed morbidity and mortality
where no approved drug therapy currently exists. Lipella completed
its initial public offering in December 2022, trading on Nasdaq
under the ticker LIPO. For more information, please visit
www.lipella.com or LinkedIn.
Forward-Looking Statements
This press release includes certain “forward-looking
statements.” All statements, other than statements of historical
fact, included in this presentation regarding, among other things,
our strategy, future operations, financial position, anticipated
dividends, projected costs, prospects, pipeline and opportunities,
sources of growth, successful implementation of our proprietary
technology, plans and objectives are forward-looking statements.
Forward-looking statements can be identified by words such as
“may,” “will,” “could,” “continue,” “would,” “should,” “potential,”
“target,” “goal,” “anticipates,” “intends,” “plans,” “seeks,”
“believes,” “estimates,” “predicts,” “expects,” “projects” and
similar references to future periods. Forward-looking statements
are based on our current expectations and assumptions regarding
future events and financial trends that we believe may affect our
financial condition, results of operations, business strategy,
short- and long-term business operations and objectives, and
financial needs. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict. Our actual
results may differ materially from those contemplated by the
forward-looking statements. We caution you, therefore, against
relying on any of these forward-looking statements. They are
neither statements of historical fact nor guarantees or assurances
of future performance. There are risks, uncertainties and other
factors, both known and unknown, that could cause actual results to
differ materially from those in the forward-looking statements
which include, but are not limited to, regional, national or global
political, economic, business, competitive, market and regulatory
conditions, and other factors. Any forward-looking statement made
by us is based upon the reasonable judgment of our management at
the time such statement is made and speaks only as of the date on
which it is made. Factors or events that could cause our actual
results to differ may emerge from time to time, and it is not
possible for us to predict all of them. We undertake no obligation
to update any forward-looking statement, whether as a result of new
information, future developments or otherwise, except as may be
required by applicable law. Nothing contained herein is, or shall
be relied upon as, a promise or representation as to the past or
future. The Company expressly disclaims any and all liability
relating to or resulting from the use of this presentation. In
addition, the information contained in this press release is as of
the date hereof, and the Company has no obligation to update such
information, including in the event that such information becomes
inaccurate. You should not construe the contents of this press
release as legal, tax and financial advisors as to legal and
related matters concerning the matters described herein.
CONTACTJonathan KaufmanLipella
PharmaceuticalsInfo@Lipella.com 1-412-894-1853
Jeff RamsonPCG
Advisoryjramson@pcgadvisory.com646.863.6341
Grafico Azioni Lipella Pharmaceuticals (NASDAQ:LIPO)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Lipella Pharmaceuticals (NASDAQ:LIPO)
Storico
Da Dic 2023 a Dic 2024